Related Experiment Video

Updated: Jun 24, 2026

Stimulation of Notch Signaling in Mouse Osteoclast Precursors
08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia

P J Real1, A A Ferrando

  • 1Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.

Leukemia
|April 10, 2009
PubMed

Insights

Gamma-secretase inhibitors targeting NOTCH1 signaling show limited efficacy in T-cell acute lymphoblastic leukemia (T-ALL) but combining them with glucocorticoids may improve outcomes and reduce gut toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • NOTCH1 signaling is a target for T-cell acute lymphoblastic leukemia (T-ALL) therapy.
  • Gamma-secretase inhibitors (GSIs) targeting NOTCH1 have shown limited antileukemic activity and significant gastrointestinal toxicity in T-ALL.
  • NOTCH1 inhibition impacts gut homeostasis, leading to side effects.

Purpose of the Study:

  • To evaluate the efficacy of combining GSIs with glucocorticoids in T-ALL.
  • To determine if this combination can overcome GSI-induced gut toxicity.
  • To explore a novel therapeutic strategy for T-ALL.

Main Methods:

  • Investigated the effects of GSIs and glucocorticoids on T-ALL cell lines and patient samples.
  • Assessed antileukemic activity and glucocorticoid sensitivity.
  • Monitored gastrointestinal toxicity in preclinical models.

Main Results:

  • NOTCH1 inhibition restored glucocorticoid sensitivity in glucocorticoid-resistant T-ALL.
  • Co-treatment with glucocorticoids mitigated GSI-induced gastrointestinal toxicity.
  • Combination therapy demonstrated potential for improved therapeutic index.

Conclusions:

  • Combination therapy with GSIs and glucocorticoids represents a promising strategy for T-ALL treatment.
  • This approach may enhance antileukemic effects while managing side effects.
  • Further clinical investigation of anti-NOTCH1 therapies in combination with glucocorticoids is warranted for T-ALL.

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...